UPDATE: Bank of America Cuts PO to $17 on Impax Laboratories on Persisting FDA Issues

By: Benzinga
Bank of America maintained Impax Laboratories (NASDAQ: IPXL ) with an Underperform rating and lowered the price objective from $20.00 to $17.00. Bank of America noted, "IPXL announced that an FDA re-inspection of its Hayward, CA facility resulted in a new Form 483 with 12 observations (three repeats). Recall that
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.